Get the Stockscreener App
1.43
3.38%
-0.05
Innate Pharma Adr stock is traded at $1.43, with a volume of 8,028.
It is down -3.38% in the last 24 hours and down -28.86% over the past month.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
See More
Previous Close:
$1.48
Open:
$1.53
24h Volume:
8,028
Relative Volume:
0.21
Market Cap:
$159.73M
Revenue:
$3.13M
Net Income/Loss:
$-55.77M
P/E Ratio:
-2.3271
EPS:
-0.6145
Net Cash Flow:
$-61.24M
1W Performance:
-11.73%
1M Performance:
-28.86%
6M Performance:
-11.73%
1Y Performance:
-33.18%
1-Day Range:
$1.43
$1.53
1-Week Range:
$1.42
$1.58
52-Week Range:
$1.17
$2.71
Innate Pharma Adr Stock (IPHA) Company Profile
Compare IPHA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.43 | 159.73M | 3.13M | -55.77M | -61.24M | -0.6145 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-26 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Sep-18-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-18-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-28-25 | Initiated | BTIG Research | Buy |
| Sep-03-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-15-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-24-20 | Initiated | Goldman | Neutral |
View All
Innate Pharma Adr Stock (IPHA) Latest News
Innate Pharma (IPHA) Edges Lower to $1.51 as ADS Holds Near the Middle of Its RangeTPO Profile - https://www.siam.in/
Innate Pharma S.A. (IPH.PA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA) - Zacks Investment Research
Innate Pharma S.A. (IPHA) stock price, news, quote and history - Yahoo Finance Australia
Innate Pharma S.A. (IPHA) stock price, news, quote and history - Yahoo Finance UK
Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track? - Yahoo Finance
Innate Pharma S.A. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:IPHA) 2026-09-22 - Seeking Alpha
Earnings call transcript: Innate Pharma beats Q2 2026 forecasts as shares slip By Investing.com - Investing.com South Africa
Innate Pharma Q2 Earnings Call Highlights - Yahoo Finance
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update - Yahoo Finance
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Innate Pharma S.A. ADSADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Nyxoah SA (NYXH) Stock Price & News - Syfe
Innate Pharma S.A. ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Innate (IPHA) Q1 2026 Earnings: EPS Comes in Below Forecast under the Current Snapshot; Trading Response: Shares Move 2.95% Higher in the Latest ReadingConsensus Beat Rate - dars.gov.et
Innate (IPHA) Q1 2026 Earnings: EPS Comes in Below Forecast under the Current Snapshot; Trading Response: Shares Move 2.95% Higher in the Latest ReadingTangible Book Value - careplusvn.com
Innate (IPHA) Results Check: EPS Comes in Below Forecast under the Current Snapshot; Closing Move: Shares Rise 8.13% in Latest TradingGAAP Earnings Report - careplusvn.com
Innate (IPHA) Results Check: EPS Comes in Below Forecast under the Current Snapshot; Closing Move: Shares Rise 8.13% in Latest TradingEarnings Miss Streak - dars.gov.et
Innate (IPHA) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Move: The Market Price Moves 2.42% Higher at the CloseFinancial Summary - careplusvn.com
Innate (IPHA) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Move: The Market Price Moves 2.42% Higher at the CloseHigh Estimate Range - dars.gov.et
Innate (IPHA) Financial Update: The EPS Result Is Below Expectation in the Latest Session; Share Move - dars.gov.et
Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ... - Yahoo Finance
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - sharewise.com
Innate Pharma Secures €30M, Extends Cash Runway Into 2028 - Yahoo Finance
Innate Pharma Announces Conference Call and Webcast - Business Wire
Innate Pharma (IPHA) Tumbles 14% to $2.18: Support Test LoomsSkew Index - careplusvn.com
Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares - Business Wire
Innate Pharma (IPHA) Edges Higher by 2.63% to $2.54, Testing Mid-Range Trading BandLeveraged ETF Flow - careplusvn.com
Innate Pharma (IPHA) Edges Higher by 2.63% to $2.54, Testing Mid-Range Trading BandDealer Delta - dars.gov.et
Innate Pharma (IPHA) Edges Higher by 2.63% to $2.54, Testing Mid-Range Trading BandUp Down Ratio - dars.gov.et
Innate Pharma Announces Proposed Offering of Ordinary Shares - Business Wire
Unusual volume stocks are being observed in Wednesday's session. - ChartMill
FY2026 EPS Estimates for Innate Pharma Reduced by Analyst - MarketBeat
Innate Pharma (IPHA) Rallies 14.9% to $2.47, Faces Key Resistance at $2.59Gap Down Bounce Plays - dars.gov.et
Innate Pharma (IPHA) Rallies 14.9% to $2.47, Faces Key Resistance at $2.59MA Cross Alert - www.dars.gov.et
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Innate Pharma stock price target raised to $7 by H.C. Wainwright on Sobi deal - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com South Africa
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com India
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer - Business Wire
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy - Benzinga
IPHA Stock Firms Up As IPH4502 Trial Hits Key Milestone - stockstotrade.com
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma - businesswire.com
Innate Pharma (IPHA) Surges 28.3% to $2.22 as Biotech Sentiment StrengthensLow Vol ETF - dars.gov.et
Innate Pharma plans phase 3 trial, names new medical officer - Investing.com
Innate Pharma plans phase 3 trial, names new medical officer By Investing.com - Investing.com India
Innate Pharma partners with Sobi on lacutamab development - Investing.com
Innate Pharma partners with Sobi on lacutamab development By Investing.com - Investing.com South Africa
IPHA Q1 2026 Earnings: Wider-than-Expected Loss, Shares Edge HigherRetail Earnings Report - careplusvn.com
Innate Pharma Adr Stock (IPHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):